



Clinical trial results:

Golimumab: A Phase 4, UK, Open Label, Single arm Study on its Utilization and Impact in Ulcerative Colitis

Summary

EudraCT number	2013-004583-56
Trial protocol	GB
Global end of trial date	25 May 2016

Results information

Result version number	v1 (current)
This version publication date	03 June 2017
First version publication date	03 June 2017

Trial information

Trial identification

Sponsor protocol code	MK-8259-032
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02092285
WHO universal trial number (UTN)	-
Other trial identifiers	Acronym: GO-COLITIS

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	25 May 2016
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	25 May 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study is to evaluate the efficacy of golimumab in maintaining a clinical response in participants with moderate-to-severe ulcerative colitis. This study consists of a 1 week screening period, a 54 week treatment period, and a 12 week follow-up period, requiring a total of 7 trial site visits: Visit 1 (screening visit, Week -1), Visit 2 (enrollment visit, Day 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 5 (Week 30) and Visit 6 (Week 54) and Visit 7 (follow-up visit, Week 66).

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 May 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 205
Worldwide total number of subjects	205
EEA total number of subjects	205

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	3
Adults (18-64 years)	184
From 65 to 84 years	18

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 225 participants were screened; 205 participants started treatment after meeting eligibility criteria.

Period 1

Period 1 title	Induction Phase
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Golimumab
-----------	-----------

Arm description:

The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.

Arm type	Experimental
Investigational medicinal product name	Golimumab
Investigational medicinal product code	
Other name	Simponi®
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

50mg or 100mg solution for injection; subcutaneous injection

Number of subjects in period 1	Golimumab
Started	205
Completed	170
Not completed	35
Relapse/recurrence	7
Physician decision	4
Consent withdrawn by subject	2
Adverse Event	7
Pregnancy	1
Lack of efficacy	14

Period 2

Period 2 title	Maintenance Phase & Follow-up
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Golimumab
------------------	-----------

Arm description:

The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.

Arm type	Experimental
Investigational medicinal product name	Golimumab
Investigational medicinal product code	
Other name	Simponi®
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

50mg or 100mg solution for injection; subcutaneous injection

Number of subjects in period 2	Golimumab
Started	170
Completed	60
Not completed	110
Relapse/recurrence	29
Physician decision	10
Consent withdrawn by subject	11
Adverse Event	22
Pregnancy	1
Non-compliance with study drug	2
Lost to follow-up	1
Protocol deviation	11
Lack of efficacy	23

Baseline characteristics

Reporting groups

Reporting group title	Golimumab
-----------------------	-----------

Reporting group description:

The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.

Reporting group values	Golimumab	Total	
Number of subjects	205	205	
Age Categorical			
Units: Subjects			
Adolescents (12-17 years)	3	3	
Adults (between 18 and 64 years)	184	184	
From 65 to 84 years	18	18	
Age Continuous			
Units: years			
arithmetic mean	39.3		
standard deviation	± 15.09	-	
Gender, Male/Female			
Units: Subjects			
Female	82	82	
Male	123	123	
Study Specific Characteristic Partial Mayo Score			
The Partial Mayo Score (Mayo Score without endoscopy) measures severity of ulcerative colitis. Three sub-scores for stool frequency, rectal bleeding, and physician's global assessment are each graded from 0 to 3 with higher scores indicating more severe disease. Individual sub-scores are then summed to provide the total score ranging from 0 (normal or inactive disease) to 9 (severe disease).			
Units: Units on a scale			
arithmetic mean	6.4		
standard deviation	± 1.4	-	

End points

End points reporting groups

Reporting group title	Golimumab
Reporting group description: The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.	
Reporting group title	Golimumab
Reporting group description: The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.	
Subject analysis set title	Golimumab Full Analysis Set
Subject analysis set type	Full analysis
Subject analysis set description: The analysis population for the evaluation of efficacy during the maintenance period was the Full Analysis Set (FAS205) consisting of participants who received at least 1 dose of golimumab.	

Primary: Percentage of Participants Meeting Partial Mayo Score Response Criteria Through Week 54

End point title	Percentage of Participants Meeting Partial Mayo Score Response Criteria Through Week 54 ^[1]
End point description: The Partial Mayo Score (Mayo Score without endoscopy) measures severity of ulcerative colitis. Three sub-scores for stool frequency, rectal bleeding, and physician's global assessment are each graded from 0 to 3 with higher scores indicating more severe disease. Individual sub-scores are then summed to provide the total score ranging from 0 (normal or inactive disease) to 9 (severe disease). Clinical response is defined as a decrease in PMS of ≥2 points and ≥30% from baseline, plus either a decrease in rectal bleeding subscore of ≥1 point or an absolute rectal bleeding subscore of ≤1. In this outcome measure, the percentage of participants starting treatment at the start of the Induction Phase (Baseline) who obtained clinical response by the end of the Induction Phase (i.e., by Week 6) and maintained clinical response through Week 54 (i.e., had positive clinical responses at both Weeks 30 and 54) are estimated.	
End point type	Primary
End point timeframe: Baseline (Week 0), Week 6, Week 30, Week 54	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned was this endpoint.

End point values	Golimumab Full Analysis Set			
Subject group type	Subject analysis set			
Number of subjects analysed	205			
Units: Percentage of Participants				
number (confidence interval 95%)	24.9 (19.1 to 31.4)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 66 weeks

Adverse event reporting additional description:

The analysis population for the evaluation of safety was the All Participants as Treated population consisting of any participant who received study medication.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

Reporting groups

Reporting group title	Golimumab
-----------------------	-----------

Reporting group description:

The first induction dose of SC golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.

Serious adverse events	Golimumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	49 / 205 (23.90%)		
number of deaths (all causes)	1		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps) PANCREATIC CARCINOMA METASTATIC			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders DEEP VEIN THROMBOSIS			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions ABORTION SPONTANEOUS			

subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
ANAPHYLACTIC REACTION			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
EMPHYSEMA			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
PULMONARY EMBOLISM			
subjects affected / exposed	2 / 205 (0.98%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Investigations			
INTERNATIONAL NORMALISED RATIO INCREASED			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
LIVER FUNCTION TEST ABNORMAL			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
ACCIDENTAL OVERDOSE			
subjects affected / exposed	3 / 205 (1.46%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
GASTROINTESTINAL STOMA COMPLICATION			

subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
POST PROCEDURAL COMPLICATION			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
BRADYCARDIA			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
MYOCARDIAL INFARCTION			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
MIGRAINE			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
CORNEAL EROSION			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ULCERATIVE KERATITIS			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
ABDOMINAL TENDERNESS			

subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
ANAL FISSURE			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
COLITIS			
subjects affected / exposed	5 / 205 (2.44%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
COLITIS ULCERATIVE			
subjects affected / exposed	23 / 205 (11.22%)		
occurrences causally related to treatment / all	0 / 23		
deaths causally related to treatment / all	0 / 0		
CONSTIPATION			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
PANCREATITIS			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
RECTAL FISSURE			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
BACK PAIN			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
BURSITIS			

subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
ANAL ABSCESS			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
APPENDICITIS			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
CLOSTRIDIUM BACTERAEemia			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
DIVERTICULITIS			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
LOWER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
PNEUMONIA			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
SEPSIS			

subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
WOUND INFECTION			
subjects affected / exposed	1 / 205 (0.49%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Golimumab		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	82 / 205 (40.00%)		
Nervous system disorders			
HEADACHE			
subjects affected / exposed	15 / 205 (7.32%)		
occurrences (all)	18		
Gastrointestinal disorders			
COLITIS			
subjects affected / exposed	15 / 205 (7.32%)		
occurrences (all)	15		
COLITIS ULCERATIVE			
subjects affected / exposed	28 / 205 (13.66%)		
occurrences (all)	29		
NAUSEA			
subjects affected / exposed	15 / 205 (7.32%)		
occurrences (all)	15		
Respiratory, thoracic and mediastinal disorders			
OROPHARYNGEAL PAIN			
subjects affected / exposed	14 / 205 (6.83%)		
occurrences (all)	15		
Infections and infestations			
NASOPHARYNGITIS			
subjects affected / exposed	20 / 205 (9.76%)		
occurrences (all)	22		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 April 2014	Amendment 01 included changes to eligibility criteria, assessment procedures, and medication delivery procedures.
26 June 2014	Amendment 02 included changes to assessment procedures, and medication accountability and delivery procedures. Consent procedure was also clarified.
17 December 2014	Amendment 03 included changes to eligibility criteria, assessment procedures, discontinuation and treatment failure criteria, list of prohibited and allowed medications, interim analysis procedures, and medication labeling procedures.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported